Posttransplantation lymphoproliferative disorder - The great mimic in liver transplantation: Appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus

Liver Transplantation

Volumn 13, Issue 6, 2007, Pages 904-912

  Koch, David G ^a   Christiansen, Lydia ^a   Lazarchick, John ^a   Stuart, Robert ^a   Willner, Ira R ^a   Reuben, Adrian ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; ARTIFICIAL HYBRIDIZATION; B CELL LYMPHOMA; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MEGADOSE; EPSTEIN BARR VIRUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOMA; PREVALENCE; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC DISEASE; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION; INFANT; LIVER; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 34250742575     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21152     Document Type: Article

References (37)

1. Sanchez W, Talwalkar J, Gores G. Will all liver transplant patients eventually die from cancer?, J Hepatology 2006; 44:13-18.
2. Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies, Transplantation 2002;74:358-362.
3. Benlloch S, Berenguer M, Prieto M, Moreno R, San Juan F, Rayon M, et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years?, Am J Transplant 2004;4:596-604.
4. Catena F, Nardo B, Liviano d'Arcangelo G, Stefoni S, Arpesella G, Faenza A, et al. De novo malignancies after organ transplantation, Transplant Proc 2001;33:1858-1859.
5. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death, Liver Transpl 2001;7:S109-S118.
6. Galve ML, Cuervas-Mons V, Figueras J, Herrero I, Mata M, Clemente G, et al. Incidence and outcome of de novo malignancies after liver transplantation, Transplant Proc 1999;31:1275-1277.
7. Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study, J Hepatol 2001;34:84-91.
8. Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F, et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival, Liver Transpl 2005; 11:89-97.
9. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation, a 20-year experience, Ann Surg 2002;236:429-437.
10. Geis WP, Iwatsuki S, Molnar Z, et al. Pseudolymphoma in renal allograft recipients. Arch Surgery 1978;113: 461-466.
11. Starzl TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy, Lancet 1984;1:583-587.
12. Nalesnik MA, Starzl TE. Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders, Transplant Sci 1994;4:61-79.
13. Ben-Ari Z, Amlot P, Lachmanan S, et al. Posttransplant lymphoproliferative disorder in liver recipients: characteristics, management, and outcome. Liver Transpl Surg 1999;5:184-191.
14. Levy M, Backman L, Husberg B, et al. De novo malignancy following liver transplantation: a single center experience. Transplant Proc 1993;25:1397-1399.
15. Nalesnik M, Demetris AJ, Fung JJ, Randhawa P, Zeevi A. Posttransplant lymphoproliferative disorders. Medscape Transplantation Clinical Management. June 9, 2000. http://transplantation.medscape.com/Medscape/ transplantation/ClinicalMgmt/.../pnt-CM.v04.htm.
16. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514-1516.
17. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion and the lymphoproliferative syndrome in pediatric liver transplant recipient. Transplant Proc 1991;23:1473-1476.
18. Steiber AC, Boillot O, Scotti Fogelieni C, et al. The surgical implications of posttransplant lymphoproliferative disorders. Transplant Proc 1991;23:1477-1479.
19. Walker RC, Paya CV, Marshall WF, et al. Pretransplant seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14:214-221.
20. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001;3:70-78.
21. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988;45:719-727.
22. Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatology 2004;40:728-735.
23. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999;68:1851-1854.
24. Andreone P, Gramenzi A, Lorenzini S, et al. Posttransplant lymphoproliferative disorders. Arch Intern Med 1997; 163: 1997-2004, 2003.
25. Lorenzini S, Anrreone P, Gramenzi A, et al. Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases. Transpl Proc 2006;38:1477-1480.
26. Aucejo F, Rofaiel G, Miller C. Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation?, J Hepatol 2006;44:19-23.
27. Duvoux C, Pageaux GP, Vanlemmens C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002;74:1103-1109.
28. Leblond V, Davi F, Charlotte F, et al. Post-transplant lymphoproliferative Disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16:2052-2059.
29. Swinnen LJ, Costanzo-Nordin MK, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990;323: 1723-1728.
30. Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000;24:375-385.
31. Poirel HA, Bernheim A, Schneider A, et al. Characteristic pattern of chromosomal imbalances in posttransplant lymphoproliferative disorders: correlation with histopathological subcategories and EBV status. Transplantation 2005;80:176-184.
32. Jaffe ES, Harris NL, Stein H., Vardiman JW, eds. World Health Organization classification of tumors, pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001;264.
33. Oertel S, Trappe RU, Zeidler K, et al. Epstein-Barr viral load in whole blood of adults with posttransplant lympho-proliferative disorder after Solid organ transplantation does not correlate with clinical course. Ann Hematol 2006; 85:478-484.
34. Andreu H, Rimola A, Bruguera M, et al. Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression: predictive factors of response to antirejection therapy. Transplantation 2002;74: 1936-1943.
35. Pfitzmann R, Klupp J, Michael J. Mycophenolatemofetal for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 2003;76: 130-136.
36. Reuben A. A sheep in wolfs clothing. Hepatology 2003;38: 1596-1601.
37. Timms JM, Bell A, Flavell JR, Murray PG, et al. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. The Lancet 2003;361: 217-223.